ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)

BACKGROUND: Bortezomib is a slowly reversible proteasome inhibitor. Anti-tumor activity of bortezomib has shown efficacy towards GBM cell lines. Study has also demonstrated that the bortezomib is a potential caspase dependent apoptosis inducer in GBM cells. Our phase II study is to assess the safety...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Kong, Xiao-Tang, Nguyen, Nhung, Choi, Yoon, Zhang, Guicheng, Nguyen, Huytram, Filka, Emese, Green, Stacy, Yong, William, Liau, Linda, Kaprealian, Tania, Pope, Whitney, Nghiemphu, Phioanh, Cloughesy, Timothy, Lassman, Andrew, Lai, Albert
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693090/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.044
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller